Solid Biosciences Inc. Pay versus Performance
The Pay versus Performance table from each proxy statement (Item 402(v)), as tagged in its XBRL, newest proxy first. Each proxy's own figures are kept, so a year restated in a later proxy appears once per proxy. PEO is the principal executive officer; NEO means the other named executive officers (average). Total shareholder return is the value of a $100 investment.
- 2025-12-31: PEO Alexander Cumbo; PEO total compensation $5.22M; PEO compensation actually paid $7.79M; Other NEO average total compensation $2.46M.
- 2024-12-31: PEO Alexander Cumbo; PEO total compensation $4.87M; PEO compensation actually paid $3.45M; Other NEO average total compensation $2.32M.
- 2023-12-31: PEO Alexander Cumbo; PEO total compensation $918.63K; PEO compensation actually paid $862.41K; Other NEO average total compensation $1.18M.
- 2024-12-31: Other NEO average total compensation $2.32M.
| Fiscal year end | PEO | PEO total compensation | PEO compensation actually paid | Other NEO average total compensation | Other NEO average compensation actually paid | Total shareholder return | Peer group total shareholder return | Net income | Company-selected measure | Proxy filed |
|---|
| 2025-12-31 | Alexander Cumbo | $5.22M | $7.79M | $2.46M | $3.48M | $104.83 | | | | 2026-04-23 |
|---|
| 2024-12-31 | Alexander Cumbo | $4.87M | $3.45M | $2.32M | $1.65M | $74.35 | | | | 2026-04-23 |
|---|
| 2023-12-31 | Alexander Cumbo | $918.63K | $862.41K | $1.18M | $1.05M | $114.13 | | | | 2026-04-23 |
|---|
| 2024-12-31 | | | | $2.32M | $1.65M | $15.24 | | -$124.70M | | 2025-04-25 |
|---|
| 2023-12-31 | | | | $1.18M | $1.05M | $23.39 | | -$96.02M | | 2025-04-25 |
|---|
| 2022-12-31 | | | | $1.08M | $825.43K | $20.50 | | -$85.98M | | 2025-04-25 |
|---|
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
|---|
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
|---|
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
|---|
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
|---|
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
|---|
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
|---|
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
|---|
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
|---|
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
|---|
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
|---|